Excited to share that our new preprint is now online! 🚀 "Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders" Grateful to my co-authors for their contributions. 👉 www.preprints.org/manuscript/2... www.preprints.org/manuscript/2...

Thrilled to share that our MD/PhD student Harry Wilton-Clark won First Place at Falling Walls Lab Edmonton 2025 🏆👏 His talk, Breaking the Wall of Rare Disease Therapies, will now represent Edmonton on the world stage in Berlin! 🌍 #FallingWallsLab #RareDisease www.ualberta.ca/en/graduate-...

Excited to share our new preprint: Local Non-Coding Regulatory Elements in the Muscular Dystrophies 🚀 We review how #lncRNAs, #miRNAs, and epigenetic regulators shape disease mechanisms in #DMD, #FSHD, #LGMD & more. www.preprints.org/manuscript/2... #preprints via @Preprints_org

New hope for Duchenne muscular dystrophy💙 Our team identified DG9, a peptide that boosts delivery of exon-skipping therapy to the heart — a key unmet need in DMD. This approach restored cardiac & skeletal muscle function in mice. www.ualberta.ca/en/medicine/... @wchriuofa.bsky.social

pleased to share that our article "Report on the Rare Disease Consortium Japan Inaugural Symposium" is now published in the Journal of Neuromuscular Diseases. doi.org/10.1177/2214... This work highlights the dedication of RDCJ and partners to advancing research and collaboration in rare diseases.

🎉 Congratulations to our graduate student Umme Sabrina Haque on receiving the prestigious WCHRI Graduate Studentship! Her work in medical genetics is helping advance therapies for neuromuscular disorders that affect children. @wchriuofa.bsky.social www.wchri.org/our-impact/s...

Excited to share our latest preprint: "Cardiac Cell and Animal Models for Duchenne Muscular Dystrophy in the Era of Gene Therapy and Precision Medicine" Now online at @PreprintsOrg! 🧬 www.preprints.org/manuscript/2... #DMD #GeneTherapy #PrecisionMedicine #Cardiology #Preprint #MuscularDystrophy

🎉 New Release! The 2nd Edition of Exon Skipping and Inclusion Therapies is now published with Springer Nature! This edition highlights new breakthroughs in RNA-targeted therapies. Grab your copy link.springer.com/book/10.1007... #ExonSkipping #RNAtherapeutics #GeneTherapy #DMD #SMA #SpringerNature

🚨 New publication alert! Our latest review on Brogidirsen & exon 44 skipping therapy for Duchenne muscular dystrophy is out in Genes. We discuss advances, challenges, and future directions for RNA-based therapies. 🔗 Read the full open-access article: www.mdpi.com/2073-4425/16...

www.preprints.org/manuscript/2... Excited to share our latest preprint: 🧬 “Brogidirsen and Exon 44 Skipping for DMD: Advances and Challenges in RNA-Based Therapy” 📄 www.preprints.org/manuscript/2... Proud of Annie Tang’s excellent work leading this review. #DMD #RNAtherapy #exonskipping #ASO

🎉 Proud to see our postdoc Dr. Hidenori Moriyama featured by @wchriuofa.bsky.social ! His work on improving ASO delivery for muscular dystrophy is bringing new hope to families. Thank you @stollerykids.bsky.social for supporting this research. #RareDisease #WCHRI www.wchri.org/our-impact/p...

🚨 Just featured in The Gateway! Our lab's work on exon skipping & antisense therapy is helping pave the way for genetic treatments that target DMD and beyond. 📰 Read the article: thegatewayonline.ca/2025/05/u-of...

🚨 New publication in Nature Communications! DG9–PMO improves nuclear delivery and exon skipping, restoring muscle & heart function in DMD models. A major step toward cardioprotective therapies. doi.org/10.1038/s414... Grateful to @wchriuofa.bsky.social @ualberta.bsky.social

🚨 We’re hiring! The Yokota Lab @ualberta.bsky.social is looking for a Postdoctoral Fellow to join our team developing cutting-edge genetic therapies for muscular dystrophy & rare diseases. 🌍 Edmonton, AB 🧪 3-year term (annual renewal) Apply by July 31 👉 jrecin.jst.go.jp/seek/SeekJor...

Honored to receive a 2025 grant from Muscular Dystrophy Canada to advance lipid nanoparticle–based therapies for Friedreich ataxia and SBMA, with a focus on supporting Indigenous communities affected by neuromuscular disorders. #FA #SBMA #GeneTherapy #IndigenousHealth muscle.ca/researchers/...

Proud to have hosted Fulbright Scholar Omar Sheikh in the Yokota Lab! As a scientist living with Becker MD, his work on genetic therapies and advocacy for inclusion in science made a lasting impact. Read about his journey. #Fulbright #MuscularDystrophy #InclusionInSTEM miusa.org/resource/per...

Our collaboration with Avidity Biosciences is officially published! Big congrats and thanks to everyone who made this possible! academic.oup.com/nar/article/...

🚀 Exciting progress in gene therapy! Our team @ualberta.bsky.social has developed a molecule that restores the muscle-repairing protein dysferlin, offering hope for individuals with dysferlinopathy. Grateful to our collaborators, patients, and supporters! www.ualberta.ca/en/folio/202...

🚀 Exciting news! Our team has been awarded a $1.3M CIHR grant to study Spinal-Bulbar Muscular Atrophy (SBMA) in Indigenous communities of the Prairie Provinces. Honored to collaborate with an incredible team of researchers & community leaders! @nmd4c.ca neuromuscularnetwork.ca/news/cihr-fu...

✨ Exciting News! ✨ I'm thrilled to share that our article, "Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?", has been published in Expert Opinion on Drug Safety! 🚀🔬 Access the full article here: www.tandfonline.com/eprint/BFZQK...